We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Arcutis Biotherapeutics, Inc. (ARQT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Arcutis Biotherapeutics, Inc. is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Arcutis Biotherapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ARQT's full-year earnings has moved 61.1% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ARQT has returned about 11.2% since the start of the calendar year. In comparison, Medical companies have returned an average of 3.9%. This shows that Arcutis Biotherapeutics, Inc. is outperforming its peers so far this year.
Benitec Biopharma Limited (BNTC - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 5.2%.
The consensus estimate for Benitec Biopharma Limited's current year EPS has increased 64.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 510 individual companies and currently sits at #73 in the Zacks Industry Rank. This group has gained an average of 5.9% so far this year, so ARQT is performing better in this area. Benitec Biopharma Limited is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Arcutis Biotherapeutics, Inc. and Benitec Biopharma Limited as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Arcutis Biotherapeutics, Inc. (ARQT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Arcutis Biotherapeutics, Inc. is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Arcutis Biotherapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ARQT's full-year earnings has moved 61.1% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ARQT has returned about 11.2% since the start of the calendar year. In comparison, Medical companies have returned an average of 3.9%. This shows that Arcutis Biotherapeutics, Inc. is outperforming its peers so far this year.
Benitec Biopharma Limited (BNTC - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 5.2%.
The consensus estimate for Benitec Biopharma Limited's current year EPS has increased 64.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 510 individual companies and currently sits at #73 in the Zacks Industry Rank. This group has gained an average of 5.9% so far this year, so ARQT is performing better in this area. Benitec Biopharma Limited is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Arcutis Biotherapeutics, Inc. and Benitec Biopharma Limited as they attempt to continue their solid performance.